GlaxoSmithkline Consumer Healthcare Ltd(Merged) Financial Statement

GlaxoSmithkline Consumer Healthcare Ltd(Merged) Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Dec 2019	Sep 2019	Jun 2019
Revenue	1,274.90	1,423.22	1,320.90
Operating Expense	886.78	949.28	913.92
Net Profit	276.63	345.31	248.08
Net Profit Margin	21.70	24.26	18.78
Earning Per Share	65.77	82.10	58.98
EBIDTA	386.61	441.64	405.16
Effective Tax Rate	23.01	15.66	33.36

Particulars	Dec 2019
Revenue	1274.90
Operating Expense	886.78
Net Profit	276.63
Net Profit Margin	21.70
Earning Per Share	65.77
EBIDTA	386.61
Effective Tax Rate	23.01

GlaxoSmithkline Consumer Healthcare Ltd(Merged) Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2019	Mar 2018	Mar 2017
Total Revenue Annual	4,782.01	4,316.52	3,991.28
Operating Expenses Annual	3,641.04	3,433.16	3,152.97
Operating Profit Annual	1,573.57	1,140.76	1,077.37
Interest Annual	0.78	2.03	2.78
Depreciation	60.35	64.14	63.87
Net Profit Annual	982.80	700.10	656.68
Tax Annual	529.49	374.26	353.74

Particulars	Mar 2019
Total Revenue Annual	4,782.01
Operating Expenses Annual	3,641.04
Operating Profit Annual	1,573.57
Interest Annual	0.78
Depreciation	60.35
Net Profit Annual	982.80
Tax Annual	529.49

GlaxoSmithkline Consumer Healthcare Ltd(Merged) Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2019	Mar 2018	Mar 2017
Cash Flow at the Beginning	614.10	700.91	1,061.67
Cash Flow from Operations	671.07	723.04	602.97
Cash Flow from Investing	-335.06	-446.45	-602.40
Cash Flow from Financing	-376.80	-363.40	-361.33
Cash Flow at the End	573.32	614.10	700.91

Particulars	Mar 2019
Cash Flow at the Beginning	614.10
Cash Flow from Operations	671.07
Cash Flow from Investing	-335.06
Cash Flow from Financing	-376.80
Cash Flow at the End	573.32

GlaxoSmithkline Consumer Healthcare Ltd(Merged) Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2019	Mar 2018	Mar 2017
PBDIT Margin (%)	32.91	26.06	24.34
PBIT Margin (%)	31.64	24.59	22.89
PBT Margin (%)	-8.93	12.48	14.66
Net PROFIT Margin (%)	20.55	15.99	14.84
Return On Networth / Equity (%)	25.93	21.19	22.18
Return On Networth /Employed (%)	38.19	30.59	31.58
Return On Assets (%)	24.87	19.83	20.48
Total Debt / Equity (X)	TBA	TBA	TBA
Asset Turnover Ratio (%)	1.21	1.24	1.38

Particulars	Mar 2019
PBDIT Margin (%)	32.91
PBIT Margin (%)	31.64
PBT Margin (%)	-8.93
Net PROFIT Margin (%)	20.55
Return On Networth / Equity (%)	25.93
Return On Networth /Employed (%)	38.19
Return On Assets (%)	24.87
Total Debt / Equity (X)	TBA
Asset Turnover Ratio (%)	1.21

GlaxoSmithkline Consumer Healthcare Ltd(Merged) Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2019	Mar 2018	Mar 2017
Fixed Assets Annual	467.21	478.07	495.92
Total Current Assets Annual	5,267.42	4,562.00	4,139.13
Non Current Assets Annual	800.67	850.66	815.55
Total Shareholders Funds Annual	4,094.71	3,485.12	3,122.67
Total Assets Annual	6,068.09	5,412.66	4,954.68

Particulars	Mar 2019
Fixed Assets Annual	467.21
Total Current Assets Annual	5,267.42
Non Current Assets Annual	800.67
Total Shareholders Funds Annual	4,094.71
Total Assets Annual	6,068.09

GlaxoSmithkline Consumer Healthcare Ltd(Merged) Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Dec 23, 2024, GlaxoSmithkline Consumer Healthcare Ltd(Merged) has a market capitalization of 30,336.20 Cr. Value Research classifies it as a Large-Cap company.

Yes, GlaxoSmithkline Consumer Healthcare Ltd(Merged) is debt-free with a debt-to-equity ratio of 0.00.

In FY 2023 , GlaxoSmithkline Consumer Healthcare Ltd(Merged) recorded a total revenue of approximately 4,782.01 Cr marking a significant milestone in the company's financial performance.

GlaxoSmithkline Consumer Healthcare Ltd(Merged)'s Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.1% annually, respectively..

GlaxoSmithkline Consumer Healthcare Ltd(Merged)'s current PE ratio is 30.87.

GlaxoSmithkline Consumer Healthcare Ltd(Merged)'s ROCE averaged 32.9% from the FY ending March 2017 to 2019, with a median of 31.8%. It peaked at 36.4% in March 2019, reflecting strong capital efficiency over the period..

GlaxoSmithkline Consumer Healthcare Ltd(Merged)'s latest EBIT is Rs. 1,513.07 Cr, surpassing the average EBIT of Rs. 1,200.88 Cr over the 5 years..